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 T-acute lymphoblastic leukemia (T-ALL) is a
heterogeneous hematopoietic neoplasm of precursor
T-cells.
 Ubiquitin is a small protein that marks proteins for
degradation at the proteasome.
 Deubiquitinating enzymes (DUBs) remove ubiquitin,
allowing targeted proteins to circumvent destruction.
 USP48 is one such DUB and is likely to be
overexpressed in patients with T-ALL.
 BRAT1 is a regulator of mTOR that contributes to cell
proliferation when present in excess.

 Prior research from this lab has shown that USP48 is
overexpressed in T-ALL cell lines.



Hypothesis
USP48, if overexpressed in T-ALL, interacts with
BRAT1 to increase cell proliferation and decrease
apoptosis, thus contributing to leukemogenesis.

MTT assay displayed decreased proliferation in
shRNA-knockdown cells.

 High level of USP48 expression correlated with poor
overall survival in patients with T-ALL.
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Figure 1. Western blot revealed high USP48 expression in
T-ALL cell lines compared to control thymus cells.
 Flow cytometry revealed that cells treated with PR-619
and shRNA showed elevated levels of apoptosis
compared to control cells.

Methods
 Cell culture: HPB-ALL cells, a T-ALL cell line, were
maintained in RPMI-1640 medium supplemented
with 4% FBS.
 PR-619 treatment: HPB-ALL cells were treated for 24
hours with varying doses of PR-619 (0 μM, 1.25 μM,
2.5 μM, 5.0 μM), a DUB inhibitor.
 shRNA knockdown: HBP-ALL cells were infected in
vitro with an shRNA, knocking down the gene that
encodes for USP48, and compared with cells
infected with a control vector.
 Flow cytometry: PR-619-treated and shRNAknockdown cells were collected to assess the degree
of apoptosis after staining with PE Annexin V and 7AAD by flow cytometry.
 MTT assay: shRNA-treated cells and control cells
were assessed for proliferation by MTT assay.
 Western blot: PR-619-treated and shRNAknockdown cells were collected for a Western blot to
assess the presence of USP48 and BRAT1.
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Figure 7. Immunohistochemical staining detected the
expression of USP48 in T-ALL bone marrow specimens.
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Figure 4. MTT assay revealed decreased proliferation in
cells with USP48-knockdown relative to control HPBALL cells. Student t-test at 72 hours revealed significant
difference in mean OD (p<0.001).


Western blot revealed that BRAT1 expression
correlated with USP48 expression.
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Figure 8. Survival analysis revealed that patients with
higher levels of USP48 expression had shorter overall
survival (p=0.0001). Median survival: low expression, 87
months (n=15); high expression, 22 months (n=17).
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Figure 2. Flow cytometry revealed that apoptosis
increased with higher concentrations of PR-619, a DUB
inhibitor.

Conclusions
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Figure 5. Western blot revealed decreased BRAT1 with
decreased level of USP48, suggesting interaction.
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Figure 3. Flow cytometry revealed increased apoptosis
in USP48-knockdown cells relative to cells infected with
control vector.
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Figure 6. Western blot revealed decreased BRAT1 with
USP48-knockdown, suggesting interaction.

 Our results show a positive relationship between
USP48 and BRAT1, suggesting a role in
leukemogenesis.
 Higher levels of USP48 expression is correlated with
poorer survival outcome.
 Knockdown and inhibition of USP48 shows
increased apoptosis and decreased proliferation.
 Inhibition of USP48 may thus present new target
therapy for patients with T-ALL.
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